Drug Interaction Report
5 potential interactions and/or warnings found for the following 2 drugs:
- Loryna (drospirenone / ethinyl estradiol)
- tovorafenib
Interactions between your drugs
ethinyl estradiol tovorafenib
Applies to: Loryna (drospirenone / ethinyl estradiol), tovorafenib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with tovorafenib may decrease the plasma concentration and efficacy of contraceptive hormones. The proposed mechanism is increased clearance due to tovorafenib-mediated induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids. According to the manufacturer, tovorafenib is predicted to decrease the peak plasma concentration and systemic exposure of sensitive 3A4 substrate midazolam by at least 20%. However, data from formal clinical drug interaction studies are not available. In addition, tovorafenib may cause fetal harm when administered to a pregnant woman.
MANAGEMENT: The manufacturer recommends that concomitant use of tovorafenib with hormonal contraceptives should generally be avoided. However, if use is considered clinically necessary, women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during coadministration with tovorafenib. Alternative or additional methods of non-hormonal birth control should be used during and for at least 28 days after tovorafenib has been ceased. In addition, male patients with female partners of reproductive potential should use effective non-hormonal contraception during treatment with tovorafenib and for at least 2 weeks after stopping tovorafenib. No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.
drospirenone tovorafenib
Applies to: Loryna (drospirenone / ethinyl estradiol), tovorafenib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with tovorafenib may decrease the plasma concentration and efficacy of contraceptive hormones. The proposed mechanism is increased clearance due to tovorafenib-mediated induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids. According to the manufacturer, tovorafenib is predicted to decrease the peak plasma concentration and systemic exposure of sensitive 3A4 substrate midazolam by at least 20%. However, data from formal clinical drug interaction studies are not available. In addition, tovorafenib may cause fetal harm when administered to a pregnant woman.
MANAGEMENT: The manufacturer recommends that concomitant use of tovorafenib with hormonal contraceptives should generally be avoided. However, if use is considered clinically necessary, women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during coadministration with tovorafenib. Alternative or additional methods of non-hormonal birth control should be used during and for at least 28 days after tovorafenib has been ceased. In addition, male patients with female partners of reproductive potential should use effective non-hormonal contraception during treatment with tovorafenib and for at least 2 weeks after stopping tovorafenib. No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.
Drug and food interactions
drospirenone food
Applies to: Loryna (drospirenone / ethinyl estradiol)
Grapefruit juice may increase the blood levels of certain medications such as drospirenone. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with drospirenone. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.
ethinyl estradiol food
Applies to: Loryna (drospirenone / ethinyl estradiol)
Information for this minor interaction is available on the professional version.
ethinyl estradiol food
Applies to: Loryna (drospirenone / ethinyl estradiol)
Information for this minor interaction is available on the professional version.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.